The Division has pioneered immunosuppression research, having been a leader in the development of cyclosporine, being the first to administer rapamycin to humans in the drug’s clinical trials and to apply a mathematical model to document the synergistic effects of this drug combination, leading to FDA approval.
The Histocompatibility and Immune Evaluation Laboratories, under the direction of Dr. Ronald H. Kerman, Professor of Surgery, provide comprehensive pre- and post-transplant immune evaluation testing for kidney, heart, liver, and pancreas transplant recipients.